Literature DB >> 22386743

Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.

Pattarachai Kiratisin1, Anan Chongthaleong, Thean Yen Tan, Evelina Lagamayo, Sally Roberts, Jemelyn Garcia, Todd Davies.   

Abstract

Resistance rates amongst Gram-negative pathogens are increasing in the Asia-Pacific region. The Comparative Activity of Carbapenem Testing (COMPACT) II study surveyed the carbapenem susceptibility and minimum inhibitory concentrations (MICs) of doripenem, imipenem and meropenem against 1260 major Gram-negative pathogens isolated from hospitalised patients at 20 centres in five Asia-Pacific countries (New Zealand, the Philippines, Singapore, Thailand and Vietnam) during 2010. Pseudomonas aeruginosa (n=625), Enterobacteriaceae (n=500), and other Gram-negative pathogens including Acinetobacter baumannii (n=135) were collected from patients with bloodstream infection (32.2%), nosocomial pneumonia including ventilator-associated pneumonia (58.1%), and complicated intra-abdominal infection (9.7%), with 36.7% being isolated from patients in an Intensive Care Unit. As high as 29.8% of P. aeruginosa and 73.0% of A. baumannii isolates were not susceptible to at least a carbapenem, whereas the majority of Enterobacteriaceae (97.2%) were susceptible to all carbapenems. Respective MIC(50)/MIC(90) values (MICs for 50% and 90% of the organisms, respectively) of doripenem, imipenem and meropenem were: 0.38/8, 1.5/32 and 0.38/16 mg/L for P. aeruginosa; 0.023/0.094, 0.25/0.5 and 0.032/0.094 mg/L for Enterobacteriaceae; and 32/64, 32/128 and 32/64 mg/L for A. baumannii. Doripenem and meropenem had comparable activity against P. aeruginosa, both being more active than imipenem. All carbapenems were highly potent against Enterobacteriaceae, although imipenem demonstrated higher MIC values than doripenem and meropenem. The three carbapenems showed less activity against A. baumannii. The high prevalence of carbapenem resistance amongst important nosocomial pathogens (P. aeruginosa and A. baumannii) warrants rigorous infection control measures and appropriate antimicrobial use in the Asia-Pacific region. Copyright Â
© 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386743     DOI: 10.1016/j.ijantimicag.2012.01.002

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  31 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

2.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

3.  Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.

Authors:  Mohd H Abdul-Aziz; Azrin N Abd Rahman; Mohd-Basri Mat-Nor; Helmi Sulaiman; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Christine E Staatz
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 4.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

5.  Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.

Authors:  Dong-Hwan Lee; Yong Kyun Kim; Kyubok Jin; Myoung Joo Kang; Young-Don Joo; Yang Wook Kim; Young Soo Moon; Jae-Gook Shin; Sungmin Kiem
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 6.  Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing.

Authors:  Hui-Yin Yow; Kayatri Govindaraju; Audrey Huili Lim; Nusaibah Abdul Rahim
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

7.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

8.  MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.

Authors:  Cédric Bretonnière; Adeline Maitte; Jocelyne Caillon; Gilles Potel; David Boutoille; Cédric Jacqueline; Christophe Guitton
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

9.  Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

Authors:  Andrew A Udy; Jeffrey Lipman; Paul Jarrett; Kerenaftali Klein; Steven C Wallis; Kashyap Patel; Carl M J Kirkpatrick; Peter S Kruger; David L Paterson; Michael S Roberts; Jason A Roberts
Journal:  Crit Care       Date:  2015-01-30       Impact factor: 9.097

10.  WGS-Based Analysis of Carbapenem-Resistant Acinetobacter baumannii in Vietnam and Molecular Characterization of Antimicrobial Determinants and MLST in Southeast Asia.

Authors:  Gamal Wareth; Jörg Linde; Ngoc H Nguyen; Tuan N M Nguyen; Lisa D Sprague; Mathias W Pletz; Heinrich Neubauer
Journal:  Antibiotics (Basel)       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.